INC Research Holdings June 15th Short Interest Update

INC Research Holdings (NASDAQ:INCR) has witnessed a drop of 9.1% or 94,248 shares in its short figure. The short interest diminution took it from 1,040,494 on May 31,2016 to 946,246 on June 15,2016. In terms of floated shares, the short interest was calculated to be 2%. The days to cover are 1 given that the daily volume averaged 770,341 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

INC Research Holdings (NASDAQ:INCR): The stock opened at $37.70 on Friday but the bulls could not build on the opening and the stock topped out at $39.49 for the day. The stock traded down to $36.80 during the day, due to lack of any buying support eventually closed down at $38.58 with a loss of -2.16% for the day. The stock had closed at $39.43 on the previous day. The total traded volume was 4,920,654 shares.

The company shares have rallied 1.47% from its 1 Year high price. On Apr 18, 2016, the shares registered one year high at $57.11 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $42.67 and the 200 Day Moving Average price is recorded at $43.35.

Stocks of INC Research Holdings (NASDAQ:INCR) rallied by 3.13% during the past week but lost 14.67% on a 4-week basis. The company has outperformed the S&P 500 by 4.84% in the past week but underperformed the index by 12.08% in the last 4 weeks.

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Companys segment Clinical Development Services offers a variety of clinical development services, including global studies, clinical monitoring, investigator recruitment, patient recruitment, data management and study reports. The Companys segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Companys segment Global Consulting provides consulting services regarding clinical trial regulatory affairs, regulatory consulting services, quality assurance audits and pharmacovigilance consulting, non-clinical consulting and medical writing consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *